Company / Return on Assets (ROA)
ArriVent BioPharma, Inc. Return on Assets (ROA) History
FY2023-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Assets (ROA)
-29.3%
FY2024
5-year range
-42.5% / -29.3%
FY2023-FY2024
Trend
+31.1%
vs FY2023
Sector context
#128 of 213
Health Care
What the data says
At -29.3%, ArriVent BioPharma, Inc.'s return on assets (roa) ranks #128 of 213 in the Health Care sector.
Based on SEC 10-K filings.
-29.3% in FY2024.
Health Care sector context is included.
Return on Assets (ROA) over time
Growth rates
- 3-Year Change
- -
- 5-Year Change
- -
- 10-Year Change
- -
Sector benchmark
#128 of 213 in Health CareTop 60% of 213This company -29.3% Sector average -24.1%
▼
-21.3% below sector average
Key checks
Key Insights
- In FY2024, return on assets (roa) increased 31.1% year-over-year.
- Currently 5.1pp below the Health Care sector average.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 5.74 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Assets (ROA)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | -29.3% | +31.1% |
| FY2023 | -42.5% | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026